Marjo Tuppurainen
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Research Interests
Marjo Tuppurainen has a total of 51 co-authors. Here are the top co-authors by number of shared publications:
- Heikki Kröger
Department of Orthopedics and Traumatology, Kuopio University Hospital, Kuopio, Finland
7 shared publications - Risto Honkanen
Kuopio Musculoskeletal Research Unit (KMRU), Surgery, Institute of Clinical Medicine, University of Eastern Finland (UEF), P.O. Box 1627, 70211, Kuopio, Finland
5 shared publications Seppo Saarikoski
4 shared publicationsEsko Alhava
2 shared publicationsHeikki Kröger
2 shared publications- Heli Koivumaa-Honkanen
Kuopio Musculoskeletal Research Unit (KMRU), Surgery, Institute of Clinical Medicine, University of Eastern Finland (UEF), P.O. Box 1627, 70211, Kuopio, Finland
2 shared publications
Latest Publications
- Open Access
- 2 July 2013
- Published by Springer Nature in BMC Psychiatry
- Vol. 13 (1) , 180
The relationship between self-reported and registry-based data on use of psychoactive medications in postmenopausal women
Self-report is commonly used as a source of information on the use of medicine. The aim of this study was to investigate the relationship between self-reported and register-based information on the use of psychoactive medication, especially in respect to antidepressants, and reasons of non-reporting. Study subjects (n = 11,031) originated from a population-based cohort of postmenopausal women born in 1932–41 from Eastern Finland who responded to a postal enquiry in 1999. Self-reported currently used prescribed medications were compared to the National prescription register data. Diuretics served as a reference for psychoactive medications. Only 44% out of 1,638 women reported their use of psychoactive medication when compared to the prescription register within a 4-month time window preceding their response to enquiry. Altogether, 55% out of 777 women reported their use of antidepressants and 29% out of 861 reported their use of other psychoactive medications. In comparison 83% reported their use of diuretics. After excluding the occasional use, an increase in sensitivity by approximately 10 percentage points was seen regardless of the group of psychoactive medication. High use and history of work disability pension due to psychiatric cause were associated with a much higher likelihood of reporting psychoactive medication use (for antidepressants 70% and 81%, respectively). For research purposes, self-reported current use of psychoactive medication seems to be a sufficient indicator for regular use of antidepressants or in respect of use of any psychoactive medication, for subjects with severe psychiatric disease.
- 2 July 2013
- Published by Springer Nature in BMC Psychiatry
- Vol. 13 (1) , 180
Open AccessThe relationship between self-reported and registry-based data on use of psychoactive medications in postmenopausal women
Self-report is commonly used as a source of information on the use of medicine. The aim of this study was to investigate the relationship between self-reported and register-based information on the use of psychoactive medication, especially in respect to antidepressants, and reasons of non-reporting. Study subjects (n = 11,031) originated from a population-based cohort of postmenopausal women born in 1932–41 from Eastern Finland who responded to a postal enquiry in 1999. Self-reported currently used prescribed medications were compared to the National prescription register data. Diuretics served as a reference for psychoactive medications. Only 44% out of 1,638 women reported their use of psychoactive medication when compared to the prescription register within a 4-month time window preceding their response to enquiry. Altogether, 55% out of 777 women reported their use of antidepressants and 29% out of 861 reported their use of other psychoactive medications. In comparison 83% reported their use of diuretics. After excluding the occasional use, an increase in sensitivity by approximately 10 percentage points was seen regardless of the group of psychoactive medication. High use and history of work disability pension due to psychiatric cause were associated with a much higher likelihood of reporting psychoactive medication use (for antidepressants 70% and 81%, respectively). For research purposes, self-reported current use of psychoactive medication seems to be a sufficient indicator for regular use of antidepressants or in respect of use of any psychoactive medication, for subjects with severe psychiatric disease.
- 1 June 2012
- Vol. 64 (3) , 195-205
HT and SERMs in the long-term management of osteoporosis.
Hormone therapy (HT) remains the treatment of choice for climacteric symptoms and for prevention and treatment of bone loss at least within ten years postmenopause. The usually prescribed HT doses have decreased during the past few years, and use of low-dose HT is becoming more popular, possibly decreasing the occurrence of unwanted side effects seen with conventional doses. HT has a fracture-reducing potential even at doses lower than usually recommended, but the positive effect of HT on bone disappears relatively soon after stopping HT. The fear of long-term side effects of HT, such as breast cancer, coronary heart disease (CHD) and thromboembolic events, has increased the demand to evaluate the role of alternative osteoporosis and fracture prevention medication in ageing women. The rapid worldwide decrease of HT use may increase the incidence of fractures if there are no compensative measures. Women who discontinue HT should be advised about rapid bone loss after HT, and given other potential treatment options. Intensive research into alternative approaches to deliver estrogenic activity to bone with no adverse effects on other tissues by using low doses of estrogen, selective estrogen receptor modulators (SERMs), or combinations of the two are ongoing. However, development of an ideal SERM has proved to be difficult, and individualization of bone-protective therapy is a remarkable challenge for professionals treating postmenopausal women.
- 1 June 2012
- Vol. 64 (3) , 195-205
HT and SERMs in the long-term management of osteoporosis.
Hormone therapy (HT) remains the treatment of choice for climacteric symptoms and for prevention and treatment of bone loss at least within ten years postmenopause. The usually prescribed HT doses have decreased during the past few years, and use of low-dose HT is becoming more popular, possibly decreasing the occurrence of unwanted side effects seen with conventional doses. HT has a fracture-reducing potential even at doses lower than usually recommended, but the positive effect of HT on bone disappears relatively soon after stopping HT. The fear of long-term side effects of HT, such as breast cancer, coronary heart disease (CHD) and thromboembolic events, has increased the demand to evaluate the role of alternative osteoporosis and fracture prevention medication in ageing women. The rapid worldwide decrease of HT use may increase the incidence of fractures if there are no compensative measures. Women who discontinue HT should be advised about rapid bone loss after HT, and given other potential treatment options. Intensive research into alternative approaches to deliver estrogenic activity to bone with no adverse effects on other tissues by using low doses of estrogen, selective estrogen receptor modulators (SERMs), or combinations of the two are ongoing. However, development of an ideal SERM has proved to be difficult, and individualization of bone-protective therapy is a remarkable challenge for professionals treating postmenopausal women.
- Open Access
- 13 September 2010
- Published by Oxford University Press (OUP) in Journal of Bone and Mineral Research
- Vol. 25 (12) , 2802
Response to understanding power calculations in clinical trials
- 13 September 2010
- Published by Oxford University Press (OUP) in Journal of Bone and Mineral Research
- Vol. 25 (12) , 2802
Open AccessResponse to understanding power calculations in clinical trials
- 31 January 2008
- Published by Springer Nature in Osteoporosis International
- Vol. 19 (8) , 1203-1210
Association between functional capacity tests and fractures: An eight-year prospective population-based cohort study
Summary This study of postmenopausal women (n = 2,928) with an eight-year follow-up revealed that impairment in functional status associated with the increased fracture risk. The standing-on-one-foot and grip strength tests and a question about self-assessed ability to move can be used to identify women with a high risk of suffering a fracture. Introduction Poor functional status has pointed to associate with injurious falls and consequent fractures. Our aim was to define association between functional capacity and fractures. Methods This study was based on the Osteoporosis Risk Factor and Prevention Study (OSTPRE). A total of 2,928 postmenopausal women took part in the functional capacity and muscle strength tests. The duration of fracture follow-up varied from 6.43 to 9.86 (mean 8.37) years and the first fracture was the end-point event for the statistical analyses. All analyses were done with Cox-regression. Results A total of 261 end-point fractures occurred. In multivariate analysis the inability to stand-on-one-foot for 10 seconds increased the risk of hip fracture (hazard ratio with 95% CI) 9.11-fold (1.98–42.00). Decreased grip strength associated with 1.05-fold (1.01–1.09) increased risk of hip fractures. Low leg extension strength associated with 1.02-fold (1.00–1.03) higher risk for all fractures. The self-assessed ability to walk less than 100 meters at baseline increased the risk of ankle 2.36-fold (1.10–5.08), hip 11.57-fold (2.73–49.15) and clinical vertebral fractures 3.85-fold (1.45–10.22). Conclusion According to these results the standing-on-one-foot less than 10 seconds, grip strength and a question about ability to walk less than 100 meters may help to predict postmenopausal fractures.
- 31 January 2008
- Published by Springer Nature in Osteoporosis International
- Vol. 19 (8) , 1203-1210
Association between functional capacity tests and fractures: An eight-year prospective population-based cohort study
Summary This study of postmenopausal women (n = 2,928) with an eight-year follow-up revealed that impairment in functional status associated with the increased fracture risk. The standing-on-one-foot and grip strength tests and a question about self-assessed ability to move can be used to identify women with a high risk of suffering a fracture. Introduction Poor functional status has pointed to associate with injurious falls and consequent fractures. Our aim was to define association between functional capacity and fractures. Methods This study was based on the Osteoporosis Risk Factor and Prevention Study (OSTPRE). A total of 2,928 postmenopausal women took part in the functional capacity and muscle strength tests. The duration of fracture follow-up varied from 6.43 to 9.86 (mean 8.37) years and the first fracture was the end-point event for the statistical analyses. All analyses were done with Cox-regression. Results A total of 261 end-point fractures occurred. In multivariate analysis the inability to stand-on-one-foot for 10 seconds increased the risk of hip fracture (hazard ratio with 95% CI) 9.11-fold (1.98–42.00). Decreased grip strength associated with 1.05-fold (1.01–1.09) increased risk of hip fractures. Low leg extension strength associated with 1.02-fold (1.00–1.03) higher risk for all fractures. The self-assessed ability to walk less than 100 meters at baseline increased the risk of ankle 2.36-fold (1.10–5.08), hip 11.57-fold (2.73–49.15) and clinical vertebral fractures 3.85-fold (1.45–10.22). Conclusion According to these results the standing-on-one-foot less than 10 seconds, grip strength and a question about ability to walk less than 100 meters may help to predict postmenopausal fractures.
- 1 January 2007
- Vol. 123 (11) , 1345-6
[Not Available].
- 1 January 2006
- Vol. 122 (2) , 133-4
[Are osteoporosis and bone fractures inherited conditions?].
- 1 January 2006
- Published by Oxford University Press (OUP) in European Journal of Endocrinology
- Vol. 154 (1) , 101-107
Hormone replacement therapy and mortality in 52- to 70-year-old women: the Kuopio Osteoporosis Risk Factor and Prevention Study
Objectives: To analyze prospectively the association between hormone replacement therapy (HRT) and mortality in women before old age. Design and methods: A group of 11 667 women (91% of the age cohort of the area) aged 52–62 years from the population-based Kuopio Osteoporosis Risk Factor and Prevention Study were followed for 7 years in 1994–2001. Information about HRT use and health events was obtained from two repeated questionnaires in 1989 and 1994. Information about deaths and causes of death from the follow-up period was obtained from the Statistics Finland. Cox’s proportional-hazards models were used to calculate risk of death related to the use of HRT. Results: At the start of follow-up, 2203 women had used HRT >5 years, 3945 women ≤5 years and 5519 women had never used it. During the follow-up, 361 deaths occurred. Compared with non-users of HRT, the adjusted hazard ratio (HR) of death from any cause was 1.05 (95% confidence interval (CI) 0.80–1.36) in women who used HRT ≤5 years and 1.06 (95% CI 0.78–1.46) in women who used HRT >5 years. The adjusted HR for coronary heart disease (CHD) mortality in women who used HRT ≤5 years was 0.79 (95% CI 0.36–1.73), and in women who used HRT >5 years, 2.16 (95% CI 0.93–4.98). For breast cancer mortality the adjusted HR for ≤5 years of HRT use was 0.96 (95% CI 0.32–2.82) and 2.62 (95% CI 0.98–7.00) for >5 years of HRT use. Conclusions: History of HRT use does not affect overall or CHD mortality in women. More than 5 years of HRT use may increase the risk of breast cancer mortality.
- 1 January 2006
- Published by Oxford University Press (OUP) in European Journal of Endocrinology
- Vol. 154 (1) , 101-107
Hormone replacement therapy and mortality in 52- to 70-year-old women: the Kuopio Osteoporosis Risk Factor and Prevention Study
Objectives: To analyze prospectively the association between hormone replacement therapy (HRT) and mortality in women before old age. Design and methods: A group of 11 667 women (91% of the age cohort of the area) aged 52–62 years from the population-based Kuopio Osteoporosis Risk Factor and Prevention Study were followed for 7 years in 1994–2001. Information about HRT use and health events was obtained from two repeated questionnaires in 1989 and 1994. Information about deaths and causes of death from the follow-up period was obtained from the Statistics Finland. Cox’s proportional-hazards models were used to calculate risk of death related to the use of HRT. Results: At the start of follow-up, 2203 women had used HRT >5 years, 3945 women ≤5 years and 5519 women had never used it. During the follow-up, 361 deaths occurred. Compared with non-users of HRT, the adjusted hazard ratio (HR) of death from any cause was 1.05 (95% confidence interval (CI) 0.80–1.36) in women who used HRT ≤5 years and 1.06 (95% CI 0.78–1.46) in women who used HRT >5 years. The adjusted HR for coronary heart disease (CHD) mortality in women who used HRT ≤5 years was 0.79 (95% CI 0.36–1.73), and in women who used HRT >5 years, 2.16 (95% CI 0.93–4.98). For breast cancer mortality the adjusted HR for ≤5 years of HRT use was 0.96 (95% CI 0.32–2.82) and 2.62 (95% CI 0.98–7.00) for >5 years of HRT use. Conclusions: History of HRT use does not affect overall or CHD mortality in women. More than 5 years of HRT use may increase the risk of breast cancer mortality.
- 1 June 2003
- Published by Oxford University Press (OUP) in Journal of Bone and Mineral Research
- Vol. 18 (6) , 1036-1042
Smoking May Impair the Bone Protective Effects of Nutritional Calcium: A Population-Based Approach
Postmenopausal women were randomly selected to investigate the effects of smoking on prevention of bone loss with nutritional calcium. DXA was performed twice, and smoking and calcium intake habits were inquired through the mail in 954 women. Smoking dampened the bone protective effects of nutritional calcium. This may reflect the pathophysiology underlying smoking-induced bone loss postmenopause. This study evaluated the effect of smoking on the bone protective properties of nutritional calcium. Of the random sample of 954 peri- and postmenopausal women selected from the Osteoporosis Risk Factor and Prevention (OSTPRE) study cohort (n = 13,100) in Kuopio, Finland, 182 had smoked at some time (ever smokers) and 772 had never smoked. Women were divided in tertiles according to self-reported dairy nutritional calcium intake (mg/day): < 648 (1st), 648-927 (2nd), > 927 (3rd). Bone mineral density at lumbar spine (LS) and femoral neck (FN) was measured with DXA at baseline in 1989-1991 and at the 5-year follow-up in 1994-1997. In a linear regression model, nutritional calcium intake did not predict annual bone loss in smokers. These results were similar in the subanalysis on 71 current smokers (at both baseline and 5-year measurements) and on 85 past smokers. In never smokers, a statistically significant linear trend was observed between calcium intake and annual bone loss at LS, but at FN only after adjustment for age, weight, hormone replacement therapy (HRT), and other covariates. In analysis of covariance (ANCOVA), no differences in bone loss rate were observed between calcium intake tertiles among smokers. In nonsmokers, the annual bone loss rate was lower in the second (-0.41%) and the third (-0.35%) tertile compared with the first tertile (-0.61%) at LS (p < 0.05) and lower in the third tertile (-0.55%) than in first tertile (-0.72%) at FN after adjustment for age, weight, HRT, and other covariates (p < 0.05). When smokers were added to the nonsmoker group, the differences in bone loss rate between calcium intake tertiles disappeared. In addition, in ANCOVA, the term of interaction between smoking and calcium intake was statistically significant at LS only. In conclusion, smoking seems to impair the bone protective effects of nutritional calcium in postmenopausal women, more clearly in LS than FN.
- 1 June 2003
- Published by Oxford University Press (OUP) in Journal of Bone and Mineral Research
- Vol. 18 (6) , 1036-1042
Smoking May Impair the Bone Protective Effects of Nutritional Calcium: A Population-Based Approach
Postmenopausal women were randomly selected to investigate the effects of smoking on prevention of bone loss with nutritional calcium. DXA was performed twice, and smoking and calcium intake habits were inquired through the mail in 954 women. Smoking dampened the bone protective effects of nutritional calcium. This may reflect the pathophysiology underlying smoking-induced bone loss postmenopause. This study evaluated the effect of smoking on the bone protective properties of nutritional calcium. Of the random sample of 954 peri- and postmenopausal women selected from the Osteoporosis Risk Factor and Prevention (OSTPRE) study cohort (n = 13,100) in Kuopio, Finland, 182 had smoked at some time (ever smokers) and 772 had never smoked. Women were divided in tertiles according to self-reported dairy nutritional calcium intake (mg/day): < 648 (1st), 648-927 (2nd), > 927 (3rd). Bone mineral density at lumbar spine (LS) and femoral neck (FN) was measured with DXA at baseline in 1989-1991 and at the 5-year follow-up in 1994-1997. In a linear regression model, nutritional calcium intake did not predict annual bone loss in smokers. These results were similar in the subanalysis on 71 current smokers (at both baseline and 5-year measurements) and on 85 past smokers. In never smokers, a statistically significant linear trend was observed between calcium intake and annual bone loss at LS, but at FN only after adjustment for age, weight, hormone replacement therapy (HRT), and other covariates. In analysis of covariance (ANCOVA), no differences in bone loss rate were observed between calcium intake tertiles among smokers. In nonsmokers, the annual bone loss rate was lower in the second (-0.41%) and the third (-0.35%) tertile compared with the first tertile (-0.61%) at LS (p < 0.05) and lower in the third tertile (-0.55%) than in first tertile (-0.72%) at FN after adjustment for age, weight, HRT, and other covariates (p < 0.05). When smokers were added to the nonsmoker group, the differences in bone loss rate between calcium intake tertiles disappeared. In addition, in ANCOVA, the term of interaction between smoking and calcium intake was statistically significant at LS only. In conclusion, smoking seems to impair the bone protective effects of nutritional calcium in postmenopausal women, more clearly in LS than FN.